Business Context and Reporting Period
This Form 8-K, dated April 14, 2022, reports on Becton, Dickinson and Company (BD). The filing addresses the completion of the separation and distribution of Embecta Corp. (formerly BD's Diabetes Care business) on April 1, 2022. The report provides recast historical financial information to present BD's standalone operating results from continuing operations, treating the Diabetes Care business as discontinued operations.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references "Exhibit 99.1" which contains the Unaudited Recast Financial Information. The document details the methodology for calculating non-GAAP measures, which exclude "specified items" such as:
- Purchase accounting adjustments and integration/restructuring costs.
- Transaction gains and losses, litigation matters, and asset impairments.
- European regulatory initiative-related costs (compliance with EU Medical Device Regulations).
- Impacts of debt extinguishment and hurricane-related insurance proceeds.
Material Changes
The primary material change is the structural separation of the Diabetes Care business into Embecta Corp. Consequently, historical financial data has been recast to exclude this segment as discontinued operations. The filing highlights that European regulatory initiative-related costs are considered unusual and duplicative of prior costs, and are excluded from adjusted results to improve period-over-period comparability.
Guidance, Outlook, and Management Commentary
Management states that non-GAAP measures are used to help investors understand underlying operational trends and future prospects by excluding items outside of core operations. The filing explicitly cautions that these non-GAAP measures are not replacements for GAAP results and should be read in conjunction with them. No specific forward-looking guidance or numerical outlook is provided within the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific recast financial figures and non-GAAP reconciliations.
- Verify the impact of the Diabetes Care separation on future revenue streams and segment reporting.
- Assess the magnitude of excluded European regulatory initiative costs to understand the difference between GAAP and non-GAAP performance.
- Confirm the treatment of the Diabetes Care business as discontinued operations in future filings.